Sanofi Pharma Ltd. | Income Statement

Fiscal year is January-December. All values INR Millions.
2013
2014
2015
2016
2017
Sales/Revenue
17,972
19,604
21,721
23,372
24,401
Cost of Goods Sold (COGS) incl. D&A
12,539
14,704
15,707
16,602
15,869
Gross Income
5,432
4,901
6,014
6,770
8,532
SG&A Expense
2,335
2,499
2,600
2,770
4,101
EBIT
3,005
2,315
3,305
-
4,248
Non Operating Income/Expense
297
245
180
216
177
Interest Expense
-
5
4
-
-
Pretax Income
3,631
3,061
3,970
4,804
5,146
Income Tax
1,233
1,090
1,594
1,762
1,886
Consolidated Net Income
2,398
1,971
2,376
3,042
3,260
Net Income
2,398
1,971
2,376
3,042
3,260
Net Income After Extraordinaries
2,144
1,305
1,538
3,042
3,260
Net Income Available to Common
2,398
1,971
2,376
3,042
3,260
EPS (Basic)
115.14
114.46
139.59
132.09
141.55
Basic Shares Outstanding
23
23
23
23
23
EPS (Diluted)
115.14
114.46
139.59
132.09
141.55
Diluted Shares Outstanding
23
23
23
23
23
EBITDA
3,927
3,281
4,435
5,171
5,270
Other Operating Expense
93
87
109
17
183
Non-Operating Interest Income
329
506
489
605
721

About Sanofi Pharma

View Profile
Address
Sanofi House
Mumbai Maharashtra 400072
India
Employees -
Website http://www.sanofiindialtd.com
Updated 09/14/2018
Sanofi India Ltd. engages in the manufacture and distribution of pharmaceutical drugs. The firm offers its products under the AllStar, Amaryl M, Amaryl M Forte, Amaryl MV, Apidra, Arava, Augeoz, Brodactam, Cardace, Cardace Protect, Cardace AM, Cardace Meto, Caspercid, Cetapin P, Cetapin XR, Cetapin V, Clexane, Daonil, Daonil M, Frisium, Insuman Rapid, Insuman Comb 25, Insuman Comb 50, Lantus, Lasilactone 50 Lasix, Metosan XR, M-Nem, Rejusite, Amaryl, Semi-Daonil, Targocid, Taxotere, Telsite, Telsite AM, Telsite AM H, Telsite H, Trental, Vogsite Md, and Zolineg brands. It also focuses on the following therapeutic areas: diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines.